as a low-risk alternative for patients who are unable or unwilling to use an IUD. The lack of data specific to aPL-positive patients using the progestin-only pill or IUD must be weighed against the risk of pregnancy-related VTE in the general population, which is >10 times that seen with estrogen-progestin contraceptive use. Pregnancy-related thrombosis risk in aPL-positive patients is not well quantified, but VTE risk is 197/10,000 women-years for pregnant patients with a single prothrombotic